{"entity":{"id":"pragmatil","kind":"trial","name":"PragmaTIL (EU Cancer Mission trial of TIL therapy with an IL-2 analogue)","aka":["PragmaTIL"],"tldr":"A European trial testing whether a gentler substitute for high-dose interleukin-2, the drug given after tumour-infiltrating lymphocyte cell therapy, can cut serious side effects while keeping the treatment working, in melanoma, lung and cervical cancer.","summary":"PragmaTIL is a Horizon Europe Cancer Mission project (CORDIS 101104684, topic HORIZON-MISS-2022-CANCER-01-03, \"Pragmatic clinical trials to optimise treatments for patients with refractory cancers\"), coordinated by the Vall d'Hebron Institute of Oncology in Barcelona, running from 1 April 2023 to 31 March 2028 with an EU contribution of about EUR 6.0 million. Tumour-infiltrating lymphocyte adoptive cell therapy normally requires high-dose interleukin-2 to expand and activate the infused cells, and its toxicity is a barrier to use. The project's objectives are to find whether an IL-2 analogue reduces the frequency of grade 3 or higher non-haematological study-related toxicity, to compare quality of life in hospital and over time, and to carry out a health technology assessment and a social return on investment analysis.\n\nClinicalTrials.gov lists it as NCT06630611, a phase 2 study sponsored by Vall d'Hebron Institute of Oncology in melanoma, non-small-cell lung cancer and cervical cancer, recruiting, with an actual start on 15 January 2025 and a planned enrolment of 40, comparing an IL-2 analogue with high-dose IL-2 after non-myeloablative lymphodepletion and TIL infusion.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov: NCT06630611","url":"https://clinicaltrials.gov/study/NCT06630611"},{"label":"CORDIS: PragmaTIL (101104684)","url":"https://cordis.europa.eu/project/id/101104684"}],"tags":[],"related":[],"cancers":["melanoma","nsclc","cervical"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["vall-dhebron","eu-mission-on-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-toxicity-qol","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The IL-2 analogue is named ANV600 in the CORDIS objective and ANV419 in the ClinicalTrials.gov title, both read on 4 November 2026; the record does not choose between them and links no drug record.","No results have been reported."],"nct":"NCT06630611","phase":"2","setting":"Melanoma, non-small-cell lung cancer and cervical cancer: tumour-infiltrating lymphocyte therapy with an IL-2 analogue versus high-dose IL-2","sponsor":"Vall d'Hebron Institute of Oncology","started":"2025-01-15","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/pragmatil/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"institution":[{"id":"eu-mission-on-cancer","kind":"institution","name":"EU Mission on Cancer (Horizon Europe)","route":"/institutions/eu-mission-on-cancer/"},{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}]}}